CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary

• Published in: Human pathology 2013-11, Vol.44 (11), p.2536-2541
• Main Authors: Desouki, Mohamed Mokhtar, MD, PhD, Lioyd, Joshua, MD, Xu, Haodong, MD, Cao, Dengfeng, MD, PhD, Barner, Ross, MD, Zhao, Chengquan, MD
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - metabolism; Carcinoid; Carcinoid Tumor - metabolism; Carcinoid Tumor - pathology; Carcinoid Tumor - secondary; CDX2; CDX2 Transcription Factor; Diagnosis, Differential; Female; Gastrointestinal Neoplasms - metabolism; Gastrointestinal Neoplasms - pathology; Homeodomain Proteins - metabolism; Humans; Immunohistochemistry; Middle Aged; Neuroendocrine; Neuroendocrine Tumors - metabolism; Neuroendocrine Tumors - pathology; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Ovarian Neoplasms - secondary; Ovary; Ovary - metabolism; Ovary - pathology; Pathology; Small intestine; Tumors
• ISSN: 0046-8177; 1532-8392
• DOI: 10.1016/j.humpath.2013.06.014

Summary Primary ovarian carcinoids and metastatic tumors share similar morphologic features. Metastatic carcinoids must be excluded from primary ones for prognostic and therapeutic reasons. Gastrointestinal neuroendocrine (carcinoid) tumors are much more common with the majority arising from small intestine and appendix. The aim of this study is to evaluate the role of immunohistochemistry for CDX2 in differentiating primary ovarian from metastatic carcinoids of primary gastrointestinal origin. Thirty primary pure ovarian carcinoids, 16 primary ovarian carcinoids arising in association with benign teratomas, 10 ovarian carcinoids metastatic from primary gastrointestinal tract and 70 gastrointestinal neuroendocrine tumors were studied for the expression of CDX2 by immunohistochemistry. CDX2 expression revealed that 40 (57.1%) of 70 cases of gastrointestinal carcinoids and 9 (90%) of 10 ovarian metastatic carcinoids showed positive nuclear staining (diffuse or focal). On the other hand, 3 (18.8%) of 16 primary carcinoids with teratomatous elements showed weak positivity. Among the 70 gastrointestinal carcinoids, CDX2 was positive in 38 (90.5%) of 42 cases in the duodenum, small intestine, appendix, and only in 2 (11.8%) of 17 cases of colorectal carcinoids and none of the 11 cases in the stomach. It is concluded that CDX2 may be a useful marker to distinguish primary ovarian carcinoid from metastasis from small intestinal and appendiceal neuroendocrine tumors.